Company: CERO
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001213900-25-079898
Chunk: 9

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 1
Chunk 9
---
 Cash flows from financing activities: 

    Proceeds from issuance of Series A Preferred Stock, net of issuance costs 
     -  
     6,757,700  
     - 
  
    Advances from shareholder 
     -  
     13,731  
     - 
  
    Payment of sponsor loans 
     -  
     (19,715) 
     - 
  
    Proceeds from exercise of Series A Preferred warrants 
     500,000  
     -  
     - 
  
    Proceeds from short-term borrowings, net 
     -  
     408,052  
     - 
  
    Payments for short term borrowings 
     -  
     (149,340) 
     - 
  
    Proceeds from share purchases under ELOC, net of issuance costs 
     2,425,906  
     2,238,488  
     - 
  
    Proceeds received from sale of Series B Preferred Stock 
     -  
     500,000  
     - 
  
    Proceeds received from sale of Series D Preferred Stock, net of issuance costs 
     2,240,180  
     -  
     - 
  
    Proceeds received from sale of common stock and warrants 
     588,000  
     -  
     - 
  
    Proceeds received from sale of pre-funded warrants, net of issuance costs 
     3,685,027  
     -  
     - 
  
    Proceeds from exercise of pre-funded warrants 
     203  
     -  
     - 
  
    Cash redemption of Series C Preferred Stock 
     (395,000) 
     -  
     - 
  
    Net cash provided by financing activities 
     9,044,316  
     9,748,916  
     - 

    Net increase (decrease) in cash and cash equivalents 
     (24,386) 
     1,769,031  
     (637,400)

    Cash, restricted cash and cash equivalents at beginning of period 
     3,327,060  
     1,877,995  
     1,601,255 

    Cash, restricted cash and cash equivalents at end of period